



August 23, 2017

Dr. John D. Musil, CEO/Founder  
Avella of Deer Valley, Inc. #38  
24416 N. 19<sup>th</sup> Ave.  
Phoenix, AZ 85085

Dear Dr. Musil:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Avella of Deer Valley, Inc. #38, located at 24416 N. 19<sup>th</sup> Avenue, Phoenix, AZ 85085, from April 17, 2017, to April 24, 2017, by the U.S. Food and Drug Administration (FDA).

When the Agency concludes that an inspection is “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Jessica Mu, Compliance Officer, at 949-608-4477.

Sincerely,

A handwritten signature in blue ink that reads 'Mark C. Saale'.

Digitally signed by Mark C. Saale -S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People, cn=Mark C. Saale -  
S,  
0.9.2342.19200300.100.1.1=1300175249  
Date: 2017.08.25 09:30:26 -07'00'

Mark C. Saale  
Acting Director, Compliance Branch  
Division of Pharmaceutical Quality Operations IV

SP: jm

Enclosure: EIR